title: Benefit of adjuvant radiotherapy in surgically staged stage I-II endometrial carcinoma.
abstract: OBJECTIVE
  This study was performed to determine the treatment outcomes and patterns of failure following external beam therapy in patients with pathological stage I-II endometrial carcinoma.
  
  
  METHODS
  Eighty-three patients with stage I-II endometrial carcinoma surgically staged who were found to have high risk factors and who received postoperative radiation therapy are the subject of this report. High risk factors were: histologic grade II-III, depth of myometrial invasion (DMI) > or =1/2, stage II, poor prognostic histology (clear cell, papillary serous cell) and lymphovascular invasion.
  
  
  RESULTS
  Recurrences were observed in six patients. The recurrences were located in the vagina (1), lung (2), liver (1), and paraaortic lymph nodes (1). Five of the six recurrences were stage IC and II. The overall survival (OS), cause-specific survival (CSS) and disease-free survival (DFS) at five years were 82.9%, 85.0% and 81.3%, respectively. DMI, grade, age and cervical stromal invasion had a significant impact on CSS.
  
  
  CONCLUSIONS
  Adjuvant radiotherapy decreases the rate of relapse in pathologically staged high-risk stage I-II endometrial carcinoma patients. After reviewing the other studies on this subject we conclude that vaginal cuff brachytherapy alone could be used in stage IA grade III and stage IB grade I-II patients because the recurrence rate is low; pelvic radiotherapy + vaginal cuff brachytherapy should be used for stage IC-II disease. Distant metastases occurred in five of our patients and represent a significant type of failure.
authors.affiliation: Department of Gynecologic Oncology, SSK Maternity Hospital, Ankara, Turkey.
authors.forename: M F
authors.initials: MF
authors.lastname: Köse
authors.forename: M
authors.initials: M
authors.lastname: Garipagaoglu
authors.forename: F
authors.initials: F
authors.lastname: Kayikçioglu
authors.forename: S
authors.initials: S
authors.lastname: Yalvaç
authors.forename: M
authors.initials: M
authors.lastname: Adli
authors.forename: Z
authors.initials: Z
authors.lastname: Koçak
authors.forename: N
authors.initials: N
authors.lastname: Boran
authors.forename: A
authors.initials: A
authors.lastname: Haberal
authors.forename: A
authors.initials: A
authors.lastname: Cakmak
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012008:Recurrence